Evofem Biosciences, Inc.
Evofem Biosciences is revolutionizing women’s sexual and reproductive healthcare with a first-in-class innovative hormone-free contraceptive and STI prevention compound in development. Evofem’s mission is to empower women by providing products that give women the control and flexibility they desire. Launched in 2020, FDA-approved Phexxi® (lactic acid, citric acid and potassium bitartrate) vaginal gel is a first-in-class hormone-free, on-demand prescription contraception that a woman can control. Fulfilling a critical unmet need in the contraceptive space, Phexxi provides an FDA-approved localized option designed for women to use at their discretion 0-60 minutes prior to each act of intercourse. Phexxi is a hormone-free birth control women have been waiting for.
We will discover and develop innovative healthcare solutions that put women first.
We will give women everywhere control of their sexual and reproductive health.
Protecting her life’s purpose is our purpose.
Women never stop evolving, and neither will we.
Evofem Biosciences is passionately committed to addressing the changing needs of women everywhere. Through smart partnerships,
we will bring products to those who need them faster and serve markets that are difficult to reach with traditional distribution channels, thereby effectively responding to the critical sexual and reproductive health concerns of millions of women.
The Company’s first commercial product, Phexxi® (lactic acid, citric acid and potassium bitartrate), is the first and only hormone-free, prescription vaginal gel approved in the United States for the prevention of pregnancy.
The Company is evaluating its investigational drug candidate EVO100 vaginal gel for the prevention of urogenital transmission of Chlamydia trachomatis infection (chlamydia) and Neisseria gonorrhoeae infection (gonorrhea) in women. In October 2020, Evofem initiated EVOGUARD, a pivotal Phase 3 clinical trial to evaluate the safety and efficacy of EVO100 for the prevention of chlamydia and gonorrhea infection in women. Top-line results are expected in 2022.
EVOGUARD builds on reported positive, statistically significant top-line data from a double-blind placebo-controlled Phase 2b clinical trial (AMPREVENCE). This landmark study met its primary and secondary endpoints, demonstrating a 50% relative risk reduction in chlamydia infection and a 78% relative risk reduction in gonorrhea infection compared to placebo. AMPREVENCE results were presented at the 2020 STD Prevention Virtual Conference (view poster).
The Company has assembled a very strong management team with significant operational experience in the biopharmaceutical market. Specifically, our senior executives have a successful track record of developing and commercializing women’s health products including Mirena, Plan B One-Step, Yasmin, YAZ, NuvaRing, Paragard and Seasonique, among others.